AstraZeneca Takes 12% Stake in Summit Therapeutics With $2 Billion Investment and Ivonescimab Combo Pact

AZN has agreed to invest $2 billion in newly issued equity in Summit Therapeutics, buying roughly 108,955 shares of preferred stock that convert into Summit common stock at a 1:1,000 ratio. Once the deal closes, AstraZeneca will hold rights equal to about 12.0% of Summit's outstanding common stock, or about 10.6% on a fully diluted basis, according to the companies' announcements. The investment is priced at the equivalent of $18.36 per common share, which Summit's filing describes as the five-day volume-weighted average price from the prior week plus 10%.

The money comes with a clinical tie-up. Summit and AstraZeneca signed a collaboration to test ivonescimab, Summit's PD-1/VEGF bispecific antibody, in combination with sonesitatug vedotin (Sone-Ve), AstraZeneca's Claudin 18.2-targeting antibody-drug conjugate, with trials in gastrointestinal cancers expected to start imminently. The two companies also signed a non-binding memorandum of understanding to pursue a broader program pairing ivonescimab with more of AstraZeneca's cancer medicines, including its antibody-drug conjugate portfolio. For AstraZeneca, the structure buys a minority position and a development partnership around one of the most closely watched immuno-oncology assets without a full takeover.

The market read it as validation. Summit shares rose 22% in premarket trading on Tuesday, according to Yahoo Finance and Investing.com, and sell-side analysts followed with bullish notes rather than any role in the deal itself: UBS reiterated a Buy rating with a $33 target, while Jefferies raised its target to $30 from $25, citing the cash infusion and strategic validation. The early spike did not hold in full. By midday our data showed Summit near $16.40, up 5.9%, which leaves the stock trading below the $18.36 price AstraZeneca is effectively paying.

What to watch next: the FDA decision on ivonescimab in EGFR-mutated non-small cell lung cancer, which coverage places on November 14, 2026, is the nearer catalyst and is part of why investors care about the stake. After that, the start of the Sone-Ve combination trials and whether the memorandum of understanding becomes a binding agreement will show how deep the partnership goes.